



Pathway Mapsへのアクセス方法

Pathway Mapsへのアクセス方法には2種類の方法があります。

1. ターゲットレコードを介したアクセス
2. TOP画面からのアクセス

CDDI-URL : <https://www.cortellis.com/drugdiscovery>

Pathway Mapsへのアクセス方法①

Quick Search Advanced Search

①ナレッジエリアをGenes & Targets、検索ボックスに任意のターゲット名を入力してSearchをクリック

Genes & Targets "PDE4D" Search

Cortellis Drug Discovery Intelligence Genes & Targets "PDE4D"

Genes & Targets Conditions Gene Variants Overview

Apply Filters Showing 1-25 of 40 Genes & Targets records for "PDE4D"

②検索結果一覧から関心のあるターゲット名をクリック

<input type="checkbox"/> ? Name	Gene Symbol	Synonym	Organism	PDB	Drugs	Drug Highest Phase	Experimental Pharmacology	Experimental Models	Path Maps
<input type="checkbox"/> phosphodiesterase 4D	PDE4D	3',5'-cyclic-AMP phosphodiesterase 4D	Homo sapiens (human)	1E9K	393	Pre-Registered	1066	24	15
		3',5'-cyclic-AMP phosphodiesterase 4D (isoform PDE4D2)		1MKD					
		3',5'-cyclic-AMP phosphodiesterase 4D (isoform PDE4D3)		1OYN					
		3',5'-cyclic-AMP phosphodiesterase 4D (isoform PDE4D4)		1PTW					

Pathway Mapsへのアクセス方法①

Cortellis Drug Discovery Intelligence Genes & Targets "PDE4D"

Related content: Drugs & Biologics (393) Genes & Targets (5) Experimental Pharmacology (1066) Experimental Models (24) Drug Metabolism (1)

phosphodiesterase 4D ③SnapshotタブからBiological Contextタブに切り替え

Snapshot Conditions Therapies Gene Variants **Biological Context**

Organism: Homo sapiens (human) Drug Highest Phase: Pre-Registered Gene Symbol: PDE4D 101 OFF-X Safety Alerts


phosphodiesterase 4D

Snapshot Conditions Therapies Gene Variants **Biological Context**

Pathway Maps ④一覧から関心のあるパスウェイマップをクリック

- Altered calcium handling in heart failure
- Desensitization of Beta-2 adrenergic receptor signaling and reduction of relaxation
- Glucocorticoids-mediated inhibition of pro-constrictory and pro-inflammatory signaling in asthmatic airway smooth muscle cells
- Immune response_IL-3 signaling via ERK and PI3K
- Immune response_IL-4 signaling
- Muscle contraction_Role of kappa-type opioid receptor in heart
- PDE4 regulation of cyto/chemokine expression in inflammatory skin diseases**
- PDE4 regulation of cyto/chemokine expression in rheumatoid arthritis

Pathway Mapsへのアクセス方法①



Pathway Mapsへのアクセス方法②

Cortellis Drug Discovery Intelligence

Quick Search

Advanced Search

All ▾

Search in Drug Discovery Intelligence



Search

① TOP画面のExploreにAllまたはTarget-condition relationshipsを選択

Explore

All ▾

View all ▾



Identify and prioritize drug targets for your condition of interest

Learn more

Explore



Identify and prioritize potential targets for your condition of interest

Learn more

Explore



Examine the biological context of your process or condition with Pathway Maps

Learn more

Explore



Find novel drug targets

Learn more

Explore

② Examine the biological context of your process or condition with Pathway Mapsをクリック

Pathway Mapsへのアクセス方法②

Pathway Maps ×

Examine the biological context of your process or condition with Pathway Maps

🔍 Type pathway map name and select

Browse the hierarchy and select Pathological Physiological

- > Musculoskeletal Diseases (1)
- > Neoplasms and Neoplastic Processes (295)
- > Nervous System Diseases (55)
- > Nutritional and Metabolic Diseases (70)
- ▼ **Skin Diseases (26)**
 - IL-13 role in Atopic Dermatitis
 - > Dermatitis, Allergic Contact (25)
- > Urogenital Diseases (1)
- > Viral and bacterial infections (34)

③カテゴリーごとに一覧となっているので、全体を見ながら
関心のあるパスウェイマップをクリック




サポートのご案内



のご活用

ログイン後に画面端に表示される「？」アイコンから様々なガイドをご利用頂けます

アクセス時に画面下部の「すべてのCookieを受け入れる」をクリックすることで、「？」アイコンが表示されます。



- アップデートのお知らせ
- 使い方ガイド
- 各種トレーニング資料
- 問い合わせ
- ユーザーコミュニケーションツールによるフィードバック

Clarivate

Cortellis Drug Discovery Intelligence

Quick Search Advanced Search

All Search in Drug Discovery Intelligence

Explore Target-condition relationships

Identify and prioritize drug targets for your condition of interest

Identify and prioritize potential targets for your condition of interest

Examine the biological context of your process or condition with Pathway Maps

Featured Patents Latest News from BioWorld Science

May 30, 2025 | WO2025107579 Compound targeting ubiquitin kras protein degradation agent, and use thereof

Proteolysis targeting chimera (PROTAC) compounds comprising an VHL binding agent coupled to GTPase KRAS targeting moiety through a linker acting as KRAS degradati...

Betta Pharmaceuticals

Cancer

Resources & updates

Product updates Stay up-to-date on the product releases

Knowledge Base Search for help articles

Get started

Training resources

Contact us

Feedback & suggestions

各種お知らせや資料へのリンク

< Training resources

Sign up for live training

Chinese training resources

Japanese training resources

All training resources

→ CDDI日本語サポートページ

→ 詳細マニュアル（英語）

(サポートサイト経由)

創薬ナレッジベースのご活用

ユーザー様のDB利用をサポートするナレッジベースを新たに搭載しました。
検索フレーズに対応した操作説明等の各種コンテンツ関連記事にアクセス可能です。

Cortellis Drug Discovery Intelligence

Quick Search Advanced Search

All Search in Drug Discovery Intelligence Search

Explore Target-condition relationships View all

Identify and prioritize drug targets for your condition of interest Learn more Explore

Identify and prioritize potential targets for your condition of interest Learn more Explore

Examine the biological context of your process or condition with Pathway Maps Learn more Explore

Find novel drug targets Learn more Explore

Featured Patents Latest News from BioWorld Science Conferences Forthcoming Conferences

May 30, 2025 | WO2025107579 Compound targeting ubiquitin kras protein degradation agent, and use thereof
Proteolysis targeting chimera (PROTAC) compounds comprising an VHL binding agent coupled to GTPase KRAS targeting moiety through a linker...
Betta Pharmaceuticals
Cancer

May 30, 2025 | WO2025109540 Macrocyclic compounds as KIF18A inhibitors
Aurigene
Cancer

May 30, 2025 | WO2025110699 Novel compound and use thereof
Protein/nucleic acid degraders comprising cereblon (CRBN) binding agents covalently bound to eukaryotic peptide chain release factor GTP...
PROTIER Biotech
Cancer

See All of Today's Featured Patents

© 2025 Clarivate Terms of Use Privacy Statement Manage cookie preferences Customer Support Training Resources Knowledge Base

Knowledge base

What can we help you with?

Heatmap Search

Top articles results

Target Condition Heatmap
Cortellis Drug Discovery Intelligence > Content > Genes & Targets

Training webinar: Using the target-condition heatmap for target validation and prioritization
Cortellis Drug Discovery Intelligence > General > Resources

Knowledge base

Cortellis Drug Discovery Intelligence > Content > Genes & Targets

Home Resources in other languages What's new / Product updates Getting Started Content

Drugs & Biologics Genes & Targets

Upload gene list Pathway maps Molecular Function, Biological Process, Subcellular Localization and Tissue

Target Condition Heatmap

Target Condition heatmap is available at Genes & Targets results and record (Conditions tab). It shows all conditions associated with a target and provides a series of scores to rank the strength of the evidence behind a target-condition association. These scores are in-house algorithms designed to facilitate the target validation process and support different use cases, with the two main use cases being:

- Target identification and prioritization.
- Indication prioritization (including drug repurposing).

glucagon like peptide 1 receptor

Table of contents

Scores Definition

Overall Score Drug Score Gene Variant Score Experimental Model Score Biomarker Use Score

ユーザーサポートご案内

日本語サポートサイト

<https://clarivate.com/life-sciences-healthcare/ja/training-support/>

日本スタッフによる日本語マニュアル・資料をご用意。

ご活用ください！

パブリックWebセミナー

<https://clarivate.com/life-sciences-healthcare/ja/training-support/training-calendar/>

ユーザー様ならどなたでも参加できるWebセミナーを年間を通じて開催。参加できなくても録画版を視聴できます。

顧客別・部署別講習会の提供

画一的な利用説明会ではなく、事前のヒアリングを経たユーザーニーズに沿ったデータベース講習会を開催しています。

製品内ガイドツアー

データベースの基本ワークフローの各ステップを解説するツアーでスムーズに使い始めていただけます。

カスタマーケア

☎ 0800-919-1307(フリーダイヤル)
(土日祝日を除く) 9:30~17:30
✉ ts.support.jp@clarivate.com

使い方やアクセスに関する
ご質問はこちらに。

専門スタッフが対応。使い方、アクセスなどにお困りの際は、気軽に日本語でお問い合わせが可能。



Think forward

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2025 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.